Oncolytics Biotech

Q2 FY2026 EarningsQ2 FY2026 missed consensus estimates on the bottom line as ramped-up clinical activities for pelareorep drove significant cost expansion. GAAP EPS of -$0.08 was in-line with the consensus mean but trailed the high-end estimate, while Net Loss (GAAP) of $9.44M was worse than the expected $10.19M (CAD-to-USD adjusted). Research and development expenses surged 122% YoY due to start-up costs for the Phase 2 mCRC study and a reclassification of stock options to liabilities, following the company's domestication to the U.S.